{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:22:43Z","timestamp":1794007363296,"version":"4.8.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Regen Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Life expectancy has increased by three decades since the mid-twentieth century. Parallel healthspan expansion has however not followed, largely impeded by the pandemic of chronic diseases afflicting a growing older population. The lag in quality of life is a recognized challenge that calls for prioritization of disease-free longevity. Contemporary communal, clinical and research trends aspiring to extend the health horizon are here outlined in the context of an evolving epidemiology. A shared action integrating public and societal endeavors with emerging interventions that target age-related multimorbidity and frailty is needed. A multidimensional buildout of a curative perspective, boosted by modern anti-senescent and regenerative technology with augmented decision making, would require dedicated resources and cost-effective validation to responsibly bridge the healthspan-lifespan gap for a future of equitable global wellbeing.<\/jats:p>","DOI":"10.1038\/s41536-021-00169-5","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T06:57:49Z","timestamp":1632380269000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":240,"title":["Longevity leap: mind the healthspan gap"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5518-8544","authenticated-orcid":false,"given":"Armin","family":"Garmany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3072-4539","authenticated-orcid":false,"given":"Satsuki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9210-009X","authenticated-orcid":false,"given":"Andre","family":"Terzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,23]]},"reference":[{"key":"169_CR1","unstructured":"United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects Highlights (ST\/ESA\/SER.A\/423). (United Nations, New York, 2019)."},{"key":"169_CR2","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1001\/jama.2018.12621","volume":"320","author":"SJ Olshansky","year":"2018","unstructured":"Olshansky, S. J. From lifespan to healthspan. JAMA 320, 1323\u20131324 (2018).","journal-title":"JAMA"},{"key":"169_CR3","unstructured":"WHO. World Health Statistics. (World Health Organization, Geneva, 2020)."},{"key":"169_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41586-018-0457-8","volume":"561","author":"L Partridge","year":"2018","unstructured":"Partridge, L., Deelen, J. & Slagboom, P. E. Facing up to the global challenges of ageing. Nature 561, 45\u201356 (2018).","journal-title":"Nature"},{"key":"169_CR5","unstructured":"WHO. World Health Statistics: Monitoring health for the SDGs, sustainable development goals. (World Health Organization, Geneva 2020)."},{"key":"169_CR6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1752-8062.2011.00295.x","volume":"4","author":"A Terzic","year":"2011","unstructured":"Terzic, A. & Waldman, S. Chronic diseases: the emerging pandemic. Clin. Transl. Sci. 4, 225\u2013226 (2011).","journal-title":"Clin. Transl. Sci."},{"key":"169_CR7","unstructured":"WHO. Global Health Estimates: Life expectancy and leading causes of death and disability (World Health Organization, Geneva, 2019)."},{"key":"169_CR8","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators.","year":"2020","unstructured":"GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396, 1204\u20131222 (2020).","journal-title":"Lancet"},{"key":"169_CR9","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S0140-6736(18)31992-5","volume":"392","author":"NCD Countdown 2030 collaborators.","year":"2018","unstructured":"NCD Countdown 2030 collaborators. NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet 392, 1072\u20131088 (2018).","journal-title":"Lancet"},{"key":"169_CR10","unstructured":"Bloom, D. E. et al. The Global Economic Burden of Noncommunicable Diseases. (World Economic Forum, Geneva 2011)."},{"key":"169_CR11","doi-asserted-by":"publisher","first-page":"e0233857","DOI":"10.1371\/journal.pone.0233857","volume":"15","author":"AM Sanford","year":"2020","unstructured":"Sanford, A. M. et al. High prevalence of geriatric syndromes in older adults. PLoS ONE 15, e0233857 (2020).","journal-title":"PLoS ONE"},{"key":"169_CR12","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/S0140-6736(19)31786-6","volume":"394","author":"EO Hoogendijk","year":"2019","unstructured":"Hoogendijk, E. O. et al. Frailty: implications for clinical practice and public health. Lancet 394, 1365\u20131375 (2019).","journal-title":"Lancet"},{"key":"169_CR13","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(19)31785-4","volume":"394","author":"E Dent","year":"2019","unstructured":"Dent, E. et al. Management of frailty: opportunities, challenges, and future directions. Lancet 394, 1376\u20131386 (2019).","journal-title":"Lancet"},{"key":"169_CR14","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1016\/S2468-2667(18)30091-4","volume":"3","author":"P Hanlon","year":"2018","unstructured":"Hanlon, P. et al. Frailty and pre-frailty in middle-aged and older adults and its association with multimorbidity and mortality: a prospective analysis of 493,737 UK Biobank participants. Lancet Public Health 3, e323\u2013e332 (2018).","journal-title":"Lancet Public Health"},{"key":"169_CR15","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1016\/S2666-7568(20)30064-7","volume":"2","author":"S Conroy","year":"2021","unstructured":"Conroy, S. & Maynou, L. Frailty: time for a new approach to health care? Lancet Healthy Longev. 2, e60\u2013e61 (2021).","journal-title":"Lancet Healthy Longev."},{"key":"169_CR16","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1016\/S2666-7568(20)30059-3","volume":"2","author":"JM Blodgett","year":"2021","unstructured":"Blodgett, J. M., Rockwood, K. & Theou, O. Changes in the severity and lethality of age-related health deficit accumulation in the USA between 1999 and 2018: a population-based cohort study. Lancet Healthy Longev. 2, e96\u2013e104 (2021).","journal-title":"Lancet Healthy Longev."},{"key":"169_CR17","unstructured":"United Nations General Assembly. Transforming our world: The 2030 Agenda for Sustainable Development. Resolution A\/RES\/70\/1. (United Nations, New York, 2015)."},{"key":"169_CR18","unstructured":"WHO. Global Status Report on Noncommunicable Diseases. (World Health Organization, Geneva, 2014)."},{"key":"169_CR19","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1126\/science.1228293","volume":"337","author":"SY Angell","year":"2012","unstructured":"Angell, S. Y., Danel, I. & DeCock, K. M. Global health. Global indicators and targets for noncommunicable diseases. Science 337, 1456\u20131457 (2012).","journal-title":"Science"},{"key":"169_CR20","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1161\/CIR.0000000000000758","volume":"141","author":"SY Angell","year":"2020","unstructured":"Angell, S. Y. et al. The American Heart Association 2030 impact goal: a presidential advisory from the American Heart Association. Circulation 141, e120\u2013e138 (2020).","journal-title":"Circulation"},{"key":"169_CR21","unstructured":"WHO. Decade of Healthy Ageing 2021\u20132030 (World Health Organization, Geneva, 2020)."},{"key":"169_CR22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1001\/jama.2020.2923","volume":"325","author":"KE Ensrud","year":"2021","unstructured":"Ensrud, K. E. Bisphosphonates for postmenopausal osteoporosis. JAMA 325, 96 (2021).","journal-title":"JAMA"},{"key":"169_CR23","doi-asserted-by":"publisher","first-page":"e2027584","DOI":"10.1001\/jamanetworkopen.2020.27584","volume":"3","author":"K Ito","year":"2020","unstructured":"Ito, K. Cost-effectiveness of screening for osteoporosis in older men with a history of falls. JAMA Netw. Open 3, e2027584 (2020).","journal-title":"JAMA Netw. Open"},{"key":"169_CR24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40273-020-00965-9","volume":"39","author":"N Li","year":"2021","unstructured":"Li, N. et al. An updated systematic review of cost-effectiveness analyses of drugs for osteoporosis. Pharmacoeconomics 39, 181\u2013209 (2021).","journal-title":"Pharmacoeconomics"},{"key":"169_CR25","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1126\/science.1259809","volume":"345","author":"DA Chokshi","year":"2014","unstructured":"Chokshi, D. A. & Farley, T. A. Health. Changing behaviors to prevent noncommunicable diseases. Science 345, 1243\u20131244 (2014).","journal-title":"Science"},{"key":"169_CR26","doi-asserted-by":"publisher","first-page":"e0223449","DOI":"10.1371\/journal.pone.0223449","volume":"14","author":"R Lachmann","year":"2019","unstructured":"Lachmann, R. et al. The accumulation of deficits approach to describe frailty. PLoS ONE 14, e0223449 (2019).","journal-title":"PLoS ONE"},{"key":"169_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/511147a","volume":"511","author":"LO Gostin","year":"2014","unstructured":"Gostin, L. O. Non-communicable diseases: healthy living needs global governance. Nature 511, 147\u2013149 (2014).","journal-title":"Nature"},{"key":"169_CR28","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/S0140-6736(19)31730-1","volume":"394","author":"TA Ghebreyesus","year":"2019","unstructured":"Ghebreyesus, T. A. Progress in beating the tobacco epidemic. Lancet 394, 548\u2013549 (2019).","journal-title":"Lancet"},{"key":"169_CR29","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1126\/science.1222569","volume":"337","author":"R Smith","year":"2012","unstructured":"Smith, R. Why a macroeconomic perspective is critical to the prevention of noncommunicable disease. Science 337, 1501\u20131503 (2012).","journal-title":"Science"},{"key":"169_CR30","doi-asserted-by":"crossref","unstructured":"Snyder-Mackler, N. et al. Social determinants of health and survival in humans and other animals. Science 368, eaax9553 (2020).","DOI":"10.1126\/science.aax9553"},{"key":"169_CR31","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.copsyc.2015.05.002","volume":"5","author":"SE Short","year":"2015","unstructured":"Short, S. E. & Mollborn, S. Social determinants and health behaviors: Conceptual frames and empirical advances. Curr. Opin. Psychol. 5, 78\u201384 (2015).","journal-title":"Curr. Opin. Psychol."},{"key":"169_CR32","doi-asserted-by":"publisher","first-page":"m3048","DOI":"10.1136\/bmj.m3048","volume":"371","author":"CA Nelson","year":"2020","unstructured":"Nelson, C. A. et al. Adversity in childhood is linked to mental and physical health throughout life. BMJ 371, m3048 (2020).","journal-title":"BMJ"},{"key":"169_CR33","doi-asserted-by":"publisher","first-page":"l251","DOI":"10.1136\/bmj.l251","volume":"364","author":"M Marmot","year":"2019","unstructured":"Marmot, M. & Bell, R. Social determinants and non-communicable diseases: time for integrated action. BMJ 364, l251 (2019).","journal-title":"BMJ"},{"key":"169_CR34","doi-asserted-by":"publisher","first-page":"020409","DOI":"10.7189\/jogh.08.020409","volume":"8","author":"J Williams","year":"2018","unstructured":"Williams, J. et al. A systematic review of associations between non-communicable diseases and socioeconomic status within low- and lower-middle-income countries. J. Glob. Health 8, 020409 (2018).","journal-title":"J. Glob. Health"},{"key":"169_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2217\/bmm.14.99","volume":"9","author":"SA Waldman","year":"2015","unstructured":"Waldman, S. A. & Terzic, A. Companion diagnostics at the intersection of personalized medicine and healthcare delivery. Biomark. Med. 9, 1\u20133 (2015).","journal-title":"Biomark. Med."},{"key":"169_CR36","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan, N., Baselga, J. & Hyman, D. M. A view on drug resistance in cancer. Nature 575, 299\u2013309 (2019).","journal-title":"Nature"},{"key":"169_CR37","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41568-020-0252-3","volume":"20","author":"M Fazio","year":"2020","unstructured":"Fazio, M., Ablain, J., Chuan, Y., Langenau, D. M. & Zon, L. I. Zebrafish patient avatars in cancer biology and precision cancer therapy. Nat. Rev. Cancer 20, 263\u2013273 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"169_CR38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","volume":"19","author":"S Boumahdi","year":"2020","unstructured":"Boumahdi, S. & de Sauvage, F. J. The great escape: tumour cell plasticity in resistance to targeted therapy. Nat. Rev. Drug Discov. 19, 39\u201356 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"169_CR39","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nrclinonc.2011.126","volume":"8","author":"TS Mok","year":"2011","unstructured":"Mok, T. S. Personalized medicine in lung cancer: what we need to know. Nat. Rev. Clin. Oncol. 8, 661\u2013668 (2011).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"169_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","volume":"17","author":"DY Oh","year":"2020","unstructured":"Oh, D. Y. & Bang, Y. J. HER2-targeted therapies: a role beyond breast cancer. Nat. Rev. Clin. Oncol. 17, 33\u201348 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"169_CR41","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1200\/JCO.20.00184","volume":"38","author":"M Sawaki","year":"2020","unstructured":"Sawaki, M. et al. Randomized controlled trial of trastuzumab with or without chemotherapy for HER2-positive early breast cancer in older patients. J. Clin. Oncol. 38, 3743\u20133752 (2020).","journal-title":"J. Clin. Oncol."},{"key":"169_CR42","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1161\/CIRCRESAHA.117.310782","volume":"122","author":"JA Leopold","year":"2018","unstructured":"Leopold, J. A. & Loscalzo, J. Emerging role of precision medicine in cardiovascular disease. Circ. Res. 122, 1302\u20131315 (2018).","journal-title":"Circ. Res."},{"key":"169_CR43","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/S0140-6736(20)32233-9","volume":"396","author":"MB Mortensen","year":"2020","unstructured":"Mortensen, M. B. & Nordestgaard, B. G. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70\u2013100 years: a contemporary primary prevention cohort. Lancet 396, 1644\u20131652 (2020).","journal-title":"Lancet"},{"key":"169_CR44","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/S2666-7568(20)30001-5","volume":"1","author":"H Wildiers","year":"2020","unstructured":"Wildiers, H. & de Glas, N. Anticancer drugs are not well tolerated in all older patients with cancer. Lancet Healthy Longev. 1, e43\u2013e47 (2020).","journal-title":"Lancet Healthy Longev."},{"key":"169_CR45","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/ggi.13796","volume":"19","author":"F Mizokami","year":"2019","unstructured":"Mizokami, F. et al. Clinical medication review type\u2009III of polypharmacy reduced unplanned hospitalizations in older adults: A meta-analysis of randomized clinical trials. Geriatr. Gerontol. Int. 19, 1275\u20131281 (2019).","journal-title":"Geriatr. Gerontol. Int."},{"key":"169_CR46","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jgs.15767","volume":"67","author":"American Geriatrics Society Beers Criteria Update Expert Panel.","year":"2019","unstructured":"American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated Beers Criteria for potentially inappropriate medication use in older adults. J. Am. Geriatr. Soc. 67, 674\u2013694 (2019).","journal-title":"J. Am. Geriatr. Soc."},{"key":"169_CR47","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1001\/jamainternmed.2019.5096","volume":"180","author":"R Romskaug","year":"2020","unstructured":"Romskaug, R. et al. Effect of clinical geriatric assessments and collaborative medication reviews by geriatrician and family physician for improving health-related quality of life in home-dwelling older patients receiving polypharmacy: A cluster randomized clinical trial. JAMA Intern. Med. 180, 181\u2013189 (2020).","journal-title":"JAMA Intern. Med."},{"key":"169_CR48","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/jgs.15634","volume":"67","author":"JB Schwartz","year":"2019","unstructured":"Schwartz, J. B. et al. Pharmacotherapy in older adults with cardiovascular disease: report from an American College of Cardiology, American Geriatrics Society, and National Institute on Aging Workshop. J. Am. Geriatr. Soc. 67, 371\u2013380 (2019).","journal-title":"J. Am. Geriatr. Soc."},{"key":"169_CR49","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0140-6736(19)31276-0","volume":"394","author":"DM Roden","year":"2019","unstructured":"Roden, D. M. et al. Pharmacogenomics. Lancet 394, 521\u2013532 (2019).","journal-title":"Lancet"},{"key":"169_CR50","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/eurheartj\/ehx487","volume":"39","author":"H Hemingway","year":"2018","unstructured":"Hemingway, H. et al. Innovative medicines initiative 2nd programme, big data for better outcomes, BigData@Heart Consortium of 20 academic and industry partners including ESC. Big data from electronic health records for early and late translational cardiovascular research: challenges and potential. Eur. Heart J. 39, 1481\u20131495 (2018).","journal-title":"Eur. Heart J."},{"key":"169_CR51","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1056\/NEJMra1814259","volume":"380","author":"A Rajkomar","year":"2019","unstructured":"Rajkomar, A., Dean, J. & Kohane, I. Machine learning in medicine. N. Engl. J. Med. 380, 1347\u20131358 (2019).","journal-title":"N. Engl. J. Med."},{"key":"169_CR52","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1126\/science.aaz3023","volume":"367","author":"D Ho","year":"2020","unstructured":"Ho, D. Artificial intelligence in cancer therapy. Science 367, 982\u2013983 (2020).","journal-title":"Science"},{"key":"169_CR53","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1056\/NEJMra1510061","volume":"375","author":"DL Bhatt","year":"2016","unstructured":"Bhatt, D. L. & Mehta, C. Adaptive designs for clinical trials. N. Engl. J. Med. 375, 65\u201374 (2016).","journal-title":"N. Engl. J. Med."},{"key":"169_CR54","doi-asserted-by":"publisher","first-page":"327ra24","DOI":"10.1126\/scitranslmed.aad7842","volume":"8","author":"PM Enriquez-Navas","year":"2016","unstructured":"Enriquez-Navas, P. M. et al. Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Sci. Transl. Med. 8, 327ra24 (2016).","journal-title":"Sci. Transl. Med."},{"key":"169_CR55","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/S1470-2045(20)30473-3","volume":"22","author":"M Extermann","year":"2021","unstructured":"Extermann, M. et al. International Society of Geriatric Oncology. Priorities for the global advancement of care for older adults with cancer: an update of the International Society of Geriatric Oncology Priorities Initiative. Lancet Oncol. 22, e29\u2013e36 (2021).","journal-title":"Lancet Oncol."},{"key":"169_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-019-1009-3","volume":"20","author":"GJ Simon","year":"2020","unstructured":"Simon, G. J. et al. Predicting diabetes clinical outcomes using longitudinal risk factor trajectories. Bmc. Med. Inform. Decis. Mak. 20, 6 (2020).","journal-title":"Bmc. Med. Inform. Decis. Mak."},{"key":"169_CR57","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41569-020-00503-2","volume":"18","author":"KC Siontis","year":"2021","unstructured":"Siontis, K. C. et al. Artificial intelligence-enhanced electrocardiography in cardiovascular disease management. Nat. Rev. Cardiol. 18, 465\u2013478 (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"169_CR58","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","volume":"153","author":"C L\u00f3pez-Ot\u00edn","year":"2013","unstructured":"L\u00f3pez-Ot\u00edn, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. The hallmarks of aging. Cell 153, 1194\u20131217 (2013).","journal-title":"Cell"},{"key":"169_CR59","doi-asserted-by":"publisher","first-page":"180250","DOI":"10.1098\/rsob.180250","volume":"9","author":"M Radman","year":"2019","unstructured":"Radman, M. Cellular parabiosis and the latency of age-related diseases. Open Biol. 9, 180250 (2019).","journal-title":"Open Biol."},{"key":"169_CR60","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jama.2018.12440","volume":"320","author":"T Tchkonia","year":"2018","unstructured":"Tchkonia, T. & Kirkland, J. L. Aging, cell senescence, and chronic disease: emerging therapeutic strategies. JAMA 320, 1319\u20131320 (2018).","journal-title":"JAMA"},{"key":"169_CR61","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jacc.2014.10.041","volume":"65","author":"A Behfar","year":"2015","unstructured":"Behfar, A. & Terzic, A. Stem cells versus senescence: the yin and yang of cardiac health. J. Am. Coll. Cardiol. 65, 48\u201350 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"169_CR62","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/nature13193","volume":"509","author":"JM van Deursen","year":"2014","unstructured":"van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439\u2013446 (2014).","journal-title":"Nature"},{"key":"169_CR63","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1126\/science.aaw1299","volume":"364","author":"JM van Deursen","year":"2019","unstructured":"van Deursen, J. M. Senolytic therapies for healthy longevity. Science 364, 636\u2013637 (2019).","journal-title":"Science"},{"key":"169_CR64","doi-asserted-by":"publisher","first-page":"e1481","DOI":"10.1210\/clinem\/dgaa728","volume":"106","author":"T Tchkonia","year":"2021","unstructured":"Tchkonia, T., Palmer, A. K. & Kirkland, J. L. New horizons: novel approaches to enhance healthspan through targeting cellular senescence and related aging mechanisms. J. Clin. Endocrinol. Metab. 106, e1481\u2013e1487 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"169_CR65","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ebiom.2019.08.069","volume":"47","author":"LJ Hickson","year":"2019","unstructured":"Hickson, L. J. et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine 47, 446\u2013456 (2019).","journal-title":"EBioMedicine"},{"key":"169_CR66","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2217\/rme-2019-0062","volume":"14","author":"MD West","year":"2019","unstructured":"West, M. D. et al. Toward a unified theory of aging and regeneration. Regen. Med. 14, 867\u2013886 (2019).","journal-title":"Regen. Med."},{"key":"169_CR67","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.tcm.2016.01.003","volume":"26","author":"A Terzic","year":"2016","unstructured":"Terzic, A. & Behfar, A. Stem cell therapy for heart failure: ensuring regenerative proficiency. Trends Cardiovasc. Med. 26, 395\u2013404 (2016).","journal-title":"Trends Cardiovasc. Med."},{"key":"169_CR68","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMra1716145","volume":"380","author":"HM Blau","year":"2019","unstructured":"Blau, H. M. & Daley, G. Q. Stem cells in the treatment of disease. N. Engl. J. Med. 380, 1748\u20131760 (2019).","journal-title":"N. Engl. J. Med."},{"key":"169_CR69","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1016\/S0140-6736(20)31250-2","volume":"395","author":"G Cossu","year":"2020","unstructured":"Cossu, G., Fears, R., Griffin, G. & Ter Meulen, V. Regenerative medicine: challenges and opportunities. Lancet 395, 1746\u20131747 (2020).","journal-title":"Lancet"},{"key":"169_CR70","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1161\/CIRCRESAHA.118.313484","volume":"123","author":"E Braunwald","year":"2018","unstructured":"Braunwald, E. Cell-based therapy in cardiac regeneration: an overview. Circ. Res. 123, 132\u2013137 (2018).","journal-title":"Circ. Res."},{"key":"169_CR71","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.2217\/rme-2020-0194","volume":"15","author":"A Terzic","year":"2020","unstructured":"Terzic, A. Regenerative medicine lexicon. Regen. Med. 15, 2325\u20132328 (2020).","journal-title":"Regen. Med."},{"key":"169_CR72","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545\u2013553 (2020).","journal-title":"N. Engl. J. Med."},{"key":"169_CR73","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1001\/jama.2018.4653","volume":"319","author":"E Martinod","year":"2018","unstructured":"Martinod, E. et al. Feasibility of bioengineered tracheal and bronchial reconstruction using stented aortic matrices. JAMA 319, 2212\u20132222 (2018).","journal-title":"JAMA"},{"key":"169_CR74","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamasurg.2020.0230","volume":"155","author":"ML Fish","year":"2020","unstructured":"Fish, M. L., Grover, R. & Schwarz, G. S. Quality-of-life outcomes in surgical vs nonsurgical treatment of breast cancer-related lymphedema: a systematic review. JAMA. Surg. 155, 513\u2013519 (2020).","journal-title":"JAMA. Surg."},{"key":"169_CR75","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1093\/eurheartj\/ehx248","volume":"38","author":"F Fern\u00e1ndez-Avil\u00e9s","year":"2017","unstructured":"Fern\u00e1ndez-Avil\u00e9s, F. et al. Global position paper on cardiovascular regenerative medicine. Eur. Heart J. 38, 2532\u20132546 (2017).","journal-title":"Eur. Heart J."},{"key":"169_CR76","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.stem.2019.10.001","volume":"25","author":"M Desgres","year":"2019","unstructured":"Desgres, M. & Menasch\u00e9, P. Clinical translation of pluripotent stem cell therapies: challenges and considerations. Cell Stem Cell 25, 594\u2013606 (2019).","journal-title":"Cell Stem Cell"},{"key":"169_CR77","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41586-019-1168-5","volume":"569","author":"A Veres","year":"2019","unstructured":"Veres, A. et al. Charting cellular identity during human in vitro \u03b2-cell differentiation. Nature 569, 368\u2013373 (2019).","journal-title":"Nature"},{"key":"169_CR78","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41576-019-0100-z","volume":"20","author":"RG Rowe","year":"2019","unstructured":"Rowe, R. G. & Daley, G. Q. Induced pluripotent stem cells in disease modelling and drug discovery. Nat. Rev. Genet. 20, 377\u2013388 (2019).","journal-title":"Nat. Rev. Genet."},{"key":"169_CR79","doi-asserted-by":"publisher","first-page":"775","DOI":"10.2217\/bmm-2020-0683","volume":"10","author":"S Yamada","year":"2021","unstructured":"Yamada, S., Jeon, R., Garmany, A., Behfar, A. & Terzic, A. Screening for regenerative therapy responders in heart failure. Biomak. Med. 10, 775\u2013783 (2021).","journal-title":"Biomak. Med."},{"key":"169_CR80","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41536-018-0056-1","volume":"3","author":"LF Rose","year":"2018","unstructured":"Rose, L. F. et al. The convergence of regenerative medicine and rehabilitation: federal perspectives. NPJ Regen. Med. 3, 19 (2018).","journal-title":"NPJ Regen. Med."},{"key":"169_CR81","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.stem.2018.02.003","volume":"22","author":"TA Rando","year":"2018","unstructured":"Rando, T. A. & Ambrosio, F. Regenerative rehabilitation: applied biophysics meets stem cell therapeutics. Cell Stem Cell 22, 306\u2013309 (2018).","journal-title":"Cell Stem Cell"},{"key":"169_CR82","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2217\/rme-2020-0178","volume":"16","author":"S Yamada","year":"2021","unstructured":"Yamada, S., Behfar, A. & Terzic, A. Regenerative medicine clinical readiness. Regen. Med. 16, 309\u2013322 (2021).","journal-title":"Regen. Med."},{"key":"169_CR83","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2217\/17460751.3.3.351","volume":"3","author":"C Mason","year":"2008","unstructured":"Mason, C. & Dunnill, P. The strong financial case for regenerative medicine and the regen industry. Regen. Med. 3, 351\u2013363 (2008).","journal-title":"Regen. Med."},{"key":"169_CR84","unstructured":"Alliance for Regenerative Medicine. Growth & Resilience in Regenerative Medicine, Annual Report (2020)."},{"key":"169_CR85","doi-asserted-by":"publisher","first-page":"24484","DOI":"10.18632\/aging.202454","volume":"12","author":"GV Mkrtchyan","year":"2020","unstructured":"Mkrtchyan, G. V. et al. ARDO 2020: From aging mechanisms to interventins. Aging 12, 24484\u201324503 (2020).","journal-title":"Aging"},{"key":"169_CR86","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/sctm.16-0487","volume":"6","author":"D Driscoll","year":"2017","unstructured":"Driscoll, D., Farnia, S., Kefalas, P. & Maziarz, R. The high cost of high tech medicine: planning ahead for market access. Stem Cells Transl. Med. 6, 1723\u20131729 (2017).","journal-title":"Stem Cells Transl. Med."},{"key":"169_CR87","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/jamaoncol.2018.0977","volume":"4","author":"M Zettler","year":"2018","unstructured":"Zettler, M. & Nabhan, C. Total cost of chimeric antigen receptor T-cell immunotherapy. JAMA Oncol. 4, 994\u2013996 (2018).","journal-title":"JAMA Oncol."},{"key":"169_CR88","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1080\/13696998.2018.1529674","volume":"21","author":"J Roth","year":"2018","unstructured":"Roth, J. et al. Cost-effectiveness of axicabtagene axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. J. Med. Econ. 21, 1238\u20131245 (2018).","journal-title":"J. Med. Econ."},{"key":"169_CR89","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1182\/blood-2019-124364","volume":"134","author":"K Kilgore","year":"2019","unstructured":"Kilgore, K. et al. Medicare patients receiving chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma: A first real-world look at patient characteristics, healthcare utilization and costs. Blood 134, 793 (2019).","journal-title":"Blood"},{"key":"169_CR90","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nn863","volume":"5","author":"P Hagell","year":"2002","unstructured":"Hagell, P. et al. Dyskinesia following neural transplantation in Parkinson\u2019s disease. Nat. Neurosci. 5, 627\u2013628 (2002).","journal-title":"Nat. Neurosci."},{"key":"169_CR91","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.parkreldis.2006.04.006","volume":"12","author":"J Hjelmgren","year":"2006","unstructured":"Hjelmgren, J. et al. Estimating the value of novel interventions for Parkinson\u2019s disease: an early decision-making model with applicationto dopamine cell replacement. Parkinsonism Relat. Disord. 12, 443\u2013452 (2006).","journal-title":"Parkinsonism Relat. Disord."},{"key":"169_CR92","doi-asserted-by":"publisher","first-page":"959","DOI":"10.2217\/rme.15.59","volume":"10","author":"PR Archibald","year":"2015","unstructured":"Archibald, P. R. & Williams, D. J. Using the cost-effectiveness of allogeneic islet transplantation to inform induced pluripotent stem cell-derived \u03b2-cell therapy reimbursement. Regen. Med. 10, 959\u2013973 (2015).","journal-title":"Regen. Med."},{"key":"169_CR93","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1002\/term.2197","volume":"11","author":"TS de Windt","year":"2017","unstructured":"de Windt, T. S. et al. Early health economic modelling of single-stage cartilage repair. Guiding implementation of technologies in regenerative medicine. J. Tissue Eng. Regen. Med. 11, 2950\u20132959 (2017).","journal-title":"J. Tissue Eng. Regen. Med."},{"key":"169_CR94","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1017\/S0266462320000781","volume":"36","author":"K Thavorn","year":"2020","unstructured":"Thavorn, K. et al. Value of mesenchymal stem cell therapy for patients with septic shock: An early health economic evaluation. Int. J. Technol. Assess. Health Care. 36, 525\u2013532 (2020).","journal-title":"Int. J. Technol. Assess. Health Care."},{"key":"169_CR95","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41409-020-0956-8","volume":"55","author":"S Fiorenza","year":"2020","unstructured":"Fiorenza, S., Ritchie, D., Ramsey, S., Turtle, C. & Roth, J. Value and affordability of CAR T-cell therapy in the United States. Bone Marrow Transplant. 55, 1706\u20131715 (2020).","journal-title":"Bone Marrow Transplant."},{"key":"169_CR96","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1001\/jama.2019.1265","volume":"321","author":"G Sanders","year":"2019","unstructured":"Sanders, G., Maciejewski, M. & Basu, A. Overview of cost-effectiveness analysis. JAMA 321, 1400\u20131401 (2019).","journal-title":"JAMA"},{"key":"169_CR97","doi-asserted-by":"crossref","unstructured":"Lloyd-Williams, H. & Hughes, D. A. A systematic review of economic evaluations of advanced therapy medicinal products. Br. J. Clin. Pharmacol. 87, 2428\u20132443 (2021).","DOI":"10.1111\/bcp.14275"},{"key":"169_CR98","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.cell.2017.08.007","volume":"170","author":"A Torkamani","year":"2017","unstructured":"Torkamani, A., Andersen, K. G., Steinhubl, S. R. & Topol, E. J. High-definition medicine. Cell 170, 828\u2013843 (2017).","journal-title":"Cell"},{"key":"169_CR99","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000513513","volume":"6","author":"N Cherbuin","year":"2021","unstructured":"Cherbuin, N. et al. Societal need for interdisciplinary ageing research: an International Alliance of Research Universities \"Ageing, Longevity and Health\" stream (IARU-ALH) position statement. Biomed. Hub. 6, 42\u201347 (2021).","journal-title":"Biomed. Hub."},{"key":"169_CR100","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/S0140-6736(16)32381-9","volume":"389","author":"V Kontis","year":"2017","unstructured":"Kontis, V. et al. Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble. Lancet 389, 1323\u20131335 (2017).","journal-title":"Lancet"},{"key":"169_CR101","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"169_CR102","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1073\/pnas.1816541116","volume":"116","author":"FC Moore","year":"2019","unstructured":"Moore, F. C., Obradovich, N., Lehner, F. & Baylis, P. Rapidly declining remarkability of temperature anomalies may obscure public perception of climate change. Proc. Natl Acad. Sci. USA 116, 4905\u20134910 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"}],"container-title":["npj Regenerative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41536-021-00169-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41536-021-00169-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41536-021-00169-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T02:56:18Z","timestamp":1699498578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41536-021-00169-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,23]]},"references-count":102,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["169"],"URL":"https:\/\/doi.org\/10.1038\/s41536-021-00169-5","relation":{},"ISSN":["2057-3995"],"issn-type":[{"value":"2057-3995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,23]]},"assertion":[{"value":"3 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors disclose no conflict of interests relevant to this work. S.Y. and A.T. are co-inventors on regenerative sciences related intellectual property disclosed to Mayo Clinic.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}